Work

Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.e14536

Authors: Paul Michael Waring, Jayesh Desai, Zbigniew Barney Rudzki, Kate Wilson, Val Gebski, Louise M. Nott, Christos Stelios Karapetis, Mustafa Khasraw, Craig Underhill, Nick Pavlakis, Lorraine A. Chantrill, Jeremy David Shapiro, Eva Segelov

Institutions: The University of Melbourne, The Royal Melbourne Hospital, National Health and Medical Research Council, Royal Hobart Hospital, Flinders University, Flinders Medical Centre, Geelong Hospital, Albury Wodonga Health, The University of Sydney, Royal North Shore Hospital, Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Cabrini Hospital, UNSW Sydney, St Vincent's Hospital Sydney

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601854146

Cites:

Cited by:

Related to: 10